Rayaldee
Rayaldee is an extended-release formulation of calcifediol (vitamin D3). It is designed to gradually raise serum 25-hydroxyvitamin D levels to normal levels, which helps to lower elevated parathyroid hormone (PTH) levels in adults with chronic kidney disease without causing sudden spikes in calcium or phosphorus.
Dosage by Body Weight
The recommended starting dose is 30 mcg administered orally once daily at bedtime. Serum calcium should be below 9.8 mg/dL before initiating treatment. The dose may be increased to 60 mcg once daily after 3 months if intact PTH remains above the target range.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients have not been established. |
| 5-7 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients have not been established. |
| 8-10 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients have not been established. |
| 11-15 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients have not been established. |
| 16-20 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients have not been established. |
Formulation
Purpose
Treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and serum total 25-hydroxyvitamin D levels less than 30 ng/mL.
Generic Name
CalcifediolScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.